Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T7417 |
Avatrombopag
YM477,AKR-501,1-[3-氯-5-[[[4-(4-氯-2-噻吩基)-5-(4-环己基-1-哌嗪基)-2-噻唑基]氨基]羰基]-2-吡啶基]-4-哌啶羧酸,E5501 |
Thrombin; Thrombopoietin Receptor | Immunology/Inflammation; Proteases/Proteasome |
Avatrombopag (YM477) 是一种新型口服血小板生成素 (TPO) 受体激动剂,可激活 TPO 受体并增加巨核细胞增殖/分化和血小板生成。 | |||
T17146 |
TPO agonist 1
|
Others | Others |
TPO agonist 1 is a thrombopoietin agonist. It would be useful as promoters of thrombopoiesis and megakaryocytopoiesis to treat thrombocytopenia. | |||
T68888 | Avatrombopag maleate | ||
Avatrombopag, also known as AKR-501, YM477, AS 1670542 or E5501, is a novel orally-active thrombopoietin (TPO) receptor agonist. AKR-501 specifically targeted the TPO receptor and stimulated megakaryocytopoiesis throughout the development and maturation of megakaryocytes just as rhTPO did. AKR-501 may be useful in the treatment of patients with thrombocytopenia. Avatrombopag was first approved in 2018. |